Phreesia, Inc.

NYSE:PHR

Medical - Healthcare Information Services

Healthcare
$12.26 +0.80%

+$0.08 today

Market cap
$760.99M
Beta
0.88
P/E (TTM)
62.6
EPS (TTM)
$0.15
52W Low $7.77High $32.76

Volume 0.86M

Average 1.97M

PHR EBITDA Margin

EBITDA as a percentage of revenue.

Phreesia, Inc.NYSE: PHR

EBITDA Margin · Q1 FY2027 · quarter ended Apr 2026

EBITDA Margin widens to 13.1%

EBITDA Margin was 13.1% in Q1 FY2027, up 9.5 pp from a year earlier. On a trailing-twelve-month basis it was 8.6%, up 10.7 pp year over year. Over 3 fiscal years it widened by 57.9 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2026 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 13 analysts of 11.7% for the fiscal year ending Jan 2027, up from 6.1% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
13.1%+9.0 pp QoQ
Last fiscal yearJan 2026
6.1%+12.2 pp YoY
LTMApr 2026
8.6%+10.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9.5 pp+9.0 pp-0.4 pp
1 year+12.2 pp+5.6 pp-6.7 pp
3 years+57.9 pp+10.8 pp-47.1 pp
5 years+13.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
6.1%
Year-over-year change
+12.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PHR compares with its peers on the latest reported figures

  • PHR's LTM Apr 2026 EBITDA Margin of 8.6% is the 4th highest of the 11 companies compared; the peer median is -1.9%.
  • Its year-over-year change of +10.7 pp is the 5th highest of 11, against a peer median of +0.8 pp.
  • Over three fiscal years its change of +57.9 pp compares with a peer median of +14.6 pp.
PHR Competitors Peer median
EBITDA Margin for PHR and competitors
Company Period LTM level YoY 3-year change
GDRXGoodRx Holdings, Inc.LTM Mar 202622.0% +0.5 pp+14.6 pp
NEOGNeogen CorporationLTM Aug 202611.9% +111.0 pp+3.8 pp
OMCLOmnicell, Inc.LTM Mar 202610.2% -0.9 pp+1.1 pp
PHRPhreesia, Inc.LTM Apr 20268.6% +10.7 pp+57.9 pp
TDOCTeladoc Health, Inc.LTM Mar 20262.3% +1.0 pp+6.1 pp
OMDAOmada HealthLTM Mar 20260.2% +15.0 pp+69.9 pp
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026-4.0% +21.1 pp+24.5 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-7.5% -19.9 pp+166.6 pp
SDGRSchrödinger, Inc.LTM Sep 2026-15.2% +50.2 pp+42.4 pp
NVCRNovoCure LimitedLTM Mar 2026-23.0% -10.7 pp-5.5 pp
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026-152.9% -23.0 pp—
Peer median (excluding PHR) -1.9%+0.8 pp+14.6 pp

Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jan 2022
FY2023
Jan 2023
FY2024
Jan 2024
FY2025
Jan 2025
FY2026
Jan 2026
Revenue213.23M280.91M356.3M419.81M480.59M
Cost of Revenue81.39M109.27M124.01M134.93M154.12M
Gross Profit131.85M171.64M232.29M284.88M326.47M
Gross Margin61.8%61.1%65.2%67.9%67.9%
Research & Development52.27M91.24M112.35M117.36M121.48M
Selling, General & Admin175.1M231.65M226.93M197.73M180.15M
Operating Expenses248.66M348.2M368.77M342.98M333.08M
Depreciation & Amortization24.52M28.77M30.54M27.89M31.45M
EBITDA(92.3M)(145.48M)(102.95M)(25.58M)29.47M
EBITDA Margin-43.3%-51.8%-28.9%-6.1%6.1%
Operating Income(116.82M)(176.55M)(136.48M)(58.1M)(6.61M)
Operating Margin-54.8%-62.9%-38.3%-13.8%-1.4%
Interest Income79K2.48M4.07M2.68M2.17M
Interest Expense1.16M1.41M1.85M2.35M6.95M
Other Income / Expenses(1.16M)889K1.14M2.29M(2.33M)
Income Before Tax(117.98M)(175.66M)(135.34M)(55.81M)(8.94M)
Pre-Tax Margin-55.3%-62.5%-38.0%-13.3%-1.9%
Income Tax Expense182K483K1.54M2.72M(11.25M)
Net Income(118.16M)(176.15M)(136.89M)(58.53M)2.31M
Net Margin-55.4%-62.7%-38.4%-13.9%0.5%
EPS (Basic)(2.37)(3.36)(2.51)(1.02)0.04
EPS (Diluted)(2.37)(3.36)(2.51)(1.02)0.04
Weighted Avg Shares49.89M52.44M54.56M57.59M59.74M
Weighted Avg Shares (Diluted)49.89M52.44M54.56M57.59M61.49M

Phreesia, Inc.

NYSE:PHR

Intrinsic Alpha fair value

Locked

Current Price

$12.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.